Trumble T E, Shon F G
Division of Hand and Microvascular Surgery, University of Washington Medical Center, Seattle, USA.
Hand Clin. 2000 Feb;16(1):105-22.
As microsurgical techniques improve, attempts to restore function after severe nerve injury place greater demands upon the use of nerve grafts. Viable Schwann cells within these grafts are necessary to maximize nerve regeneration. Progress in decreasing nerve allograft antigenicity and the host response through immunosuppression may provide results comparable to nerve autografts. Although pretreatment methods aimed at reducing allograft antigenicity have yielded inconsistent and overall unsatisfactory results, cryopreservation can maintain Schwann cell viability and shows promise as a means of tissue banking. In addition, tissue typing for MHC I or II antigens and advances in immunosuppressive therapy have rendered encouraging results in experimental models. The use of transplanted nerve allografts remains experimental, yet efforts to understand the host rejection response, advances in immunotherapy, and the development of neurotrophic factors continue to reveal significant benefits over standard treatment methods.
随着显微外科技术的进步,在严重神经损伤后恢复功能的尝试对神经移植的应用提出了更高的要求。这些移植体内有活力的施万细胞对于最大限度地促进神经再生是必要的。通过免疫抑制降低神经同种异体移植物抗原性和宿主反应方面的进展可能会提供与自体神经移植相当的结果。尽管旨在降低同种异体移植物抗原性的预处理方法产生了不一致且总体上不尽人意的结果,但冷冻保存可以维持施万细胞的活力,并有望作为一种组织储存方法。此外,针对MHC I或II抗原的组织分型以及免疫抑制疗法的进展在实验模型中取得了令人鼓舞的结果。移植神经同种异体移植物的应用仍处于实验阶段,但对宿主排斥反应的理解、免疫治疗的进展以及神经营养因子的开发继续显示出比标准治疗方法有显著优势。